NanoViricides Closes $2 Million Registered Direct Offering

NanoViricides, Inc., known for its innovation in broad-spectrum antivirals, has concluded its registered direct offering. The offering involved 1,333,334 common shares or pre-funded warrants, plus accompanying warrants for the same number of common shares. This transaction targeted a key institutional investor, with shares priced at $1.50 each and accompanying warrants exercisable at $1.75 within three years, starting six months post-issuance.

The offering, guided by D. Boral Capital LLC as the exclusive placement agent, generated gross proceeds of approximately $2 million before expenses. Shares were offered under an effective shelf registration statement on Form S-3, as filed with the SEC in May 2023. This arrangement ensures compliance with regulatory standards, with related documents available via the SEC's website.